Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 12/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27738209 | 0.97 | PARP1 (0.94) | PARP1PARP2PARP3 | |
| SCHEMBL2263821 | 0.89 | PARP1 (0.80) | PARP1PARP2PARP3 | |
| SCHEMBL2264036 | 0.88 | PARP1 (0.79) | PARP1PARP2PARP3 | |
| SCHEMBL2264064 | 0.87 | PARP1 (1.00) | PARP1PARP2PARP3 | |
| SCHEMBL2267025 | 0.87 | PARP1 (0.77) | PARP1PARP2PARP3 | |
| SCHEMBL23598274 | 0.87 | PARP1 (0.77) | PARP1PARP2PARP3 | |
| Hydrochloric Acid SCHEMBL2263931 | 0.87 | PARP1 (0.77) | PARP1PARP2PARP3 | |
| SCHEMBL16635588 | 0.87 | PARP1 (0.77) | PARP1PARP2PARP3 | |
| SCHEMBL2263507 | 0.86 | PARP1 (0.76) | PARP1PARP2PARP3 | |
| SCHEMBL2265628 | 0.86 | PARP1 (1.00) | PARP1PARP2PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | claimed |
| EP-4112049-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | Fukang (Shanghai) Health Technology Co., Ltd. (CN) | 2023-01-04 | — | — | EP | claimed |
| CN-113288892-A | Application of poly ADP ribose polymerase inhibitor in resisting coronavirus | 甫康（上海）健康科技有限责任公司 | 2021-08-24 | — | — | CN | claimed |
| CN-113288892-B | Use of poly ADP-ribose polymerase inhibitors against coronaviruses | 甫康（上海）健康科技有限责任公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2023233295-A1 | THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023201338-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A PARP INHIBITOR | IDEAYA BIOSCIENCES, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023077126-A1 | TRANS-CYCLOOCTENE CONJUGATES | TAMBO, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-4112049-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | Fukang (Shanghai) Health Technology Co., Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-106008460-B | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | 默沙东公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-101932572-A | Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide | MERCK & CO INC | 2010-12-29 | — | — | CN | disclosed |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
| EP-2109608-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-10-21 | — | — | EP | disclosed |
| CN-101415686-A | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-04-22 | — | — | CN | disclosed |
| EP-2007733-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008084261-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
| WO-2007113596-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | PARP1 1/4885PARP2 3/4885PARP3 2/4885 |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | PARP1, PARP12, PARP15 | PARP1 1/4885PARP2 6/4885PARP3 7/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | PARP1 2/4885PARP2 14/4885PARP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.